Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 4/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.40 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1439294 | 1.00 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL699327 | 1.00 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL3547377 | 1.00 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL729546 | 1.00 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL3534892 | 1.00 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL3542501 | 1.00 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL1303905 | 1.00 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL788022 | 1.00 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Hydrochloric Acid SCHEMBL833267 | 0.98 | CHRNB2 (0.41) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Hydrochloric Acid SCHEMBL3862327 | 0.98 | CHRNB2 (0.41) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117924139-A | Amplifying synthesis method of Fmoc-Hyp (tBu) -OH | 康化（上海）新药研发有限公司 | 2024-04-26 | — | — | CN | claimed |
| CN-112010914-B | Glucosamine modified pentacyclic piperazine dione and preparation and application thereof | 首都医科大学 | 2023-06-27 | — | — | CN | claimed |
| CN-112010937-B | YIGSR modified pentacyclic piperazinedione and preparation and application thereof | 首都医科大学（CN） | 2023-01-13 | — | — | CN | claimed |
| CN-112010930-A | RGD modified pentacyclic piperazinedione and preparation and application thereof | 首都医科大学 | 2020-12-01 | — | — | CN | claimed |
| CN-112010937-A | YIGSR modified pentacyclic piperazinedione and preparation and application thereof | 首都医科大学 | 2020-12-01 | — | — | CN | claimed |
| CN-112010914-A | Glucosamine-modified pentacyclic piperazinedione and preparation and application thereof | 首都医科大学 | 2020-12-01 | — | — | CN | claimed |
| CN-111995658-A | LDV (laser direct structuring) modified pentacyclic piperazinedione and preparation and application thereof | 首都医科大学 | 2020-11-27 | — | — | CN | claimed |
| CN-105175491-B | A kind of polypeptide NS3 serpin and its preparation method and application containing hydroxyproline skeleton | 山东大学 | 2019-01-11 | — | — | CN | claimed |
| CN-104844495-A | Synthesis method of (2S,4S)-4-thiophenyl-L-proline hydrochloride | UNIV WUHAN TECH | 2015-08-19 | — | — | CN | claimed |
| JP-7126247-A | — | — | None | — | — | JP | disclosed |
| US-20260144788-A1 | COMPOUND FOR SHP2 PROTEIN DEGRADATION AND MEDICAL USES THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2026-05-28 | — | — | US | disclosed |
| CN-116507617-B | 1- (2- (4-Cyclopropyl-1H-1, 2, 3-triazol-1-yl) acetyl) -4-hydroxypyrrolidine-2-carboxamide derivatives as VHL inhibitors | 基因泰克公司 | 2026-05-22 | — | — | CN | disclosed |
| CN-122070282-A | Pyrazole-1-carboxamides as RIP1 kinase inhibitors | 比西切姆有限公司 | 2026-05-19 | — | — | CN | disclosed |
| EP-4741399-A1 | LINCOSAMIDE ANTIBIOTICS AND USES THEREOF | President And Fellows Of Harvard College (US) | 2026-05-13 | — | — | EP | disclosed |
| EP-0109047-A1 | Total synthesis of antitumor antibiotics | Bristol-Myers Company (US) | 1984-05-23 | — | — | EP | disclosed |
| US-4427587-A | COUPLING ALKYL ESTER OF 4-HYDROXY PROLINE WITH NITRO, OXY, AROMATIC ACID, REDUCING NITRO GROUP AND CYCLIZATION | BRISTOL-MYERS COMPANY (US) | 1984-01-24 | — | — | US | disclosed |
| US-4329473-A | HYPOTENSIVE AGENTS | SRI INTERNATIONAL | 1982-05-11 | — | — | US | disclosed |
| EP-0042639-A2 | Azido, imido, amido and amino derivatives of mercaptoacyl prolines and pipecolic acids having hypotensive activity | E.R. Squibb & Sons, Inc. (US) | 1981-12-30 | — | — | EP | disclosed |
| US-4308388-A | HYPOTENSIVE; INHIBITS CONVERSION OF ANGIOTENSIN I TO ANGIOTENSIN II | E. R. SQUIBB & SONS, INC. (US) | 1981-12-29 | — | — | US | disclosed |
| US-4296033-A | INHIBITOR OF ANGIOTENSIN CONVERTING ENZYME, HYPOTENSIVE AGENT | E. R. SQUIBB & SONS, INC. (US) | 1981-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144788-A1 | COMPOUND FOR SHP2 PROTEIN DEGRADATION AND MEDICAL USES THEREOF | PTPN6, PTPN1, PTPN11 | CHRNB2 4589/4885CHRNA4 4839/4885CHRNB4 4721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.